| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Equipe mixte Inserm Institut National de la Santé et de la Recherche Médicale, and Service d’Urologie;
2 Département de Biochimie et Génétique, Université Paris XII, Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor; and
3 Unité mixte de Recherche, Centre National de la Recherche Scientifique, Institut Curie, Paris, France
FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liquid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3 mutations were associated with low-stage (P < 0.0001), low-grade (P < 0.008) tumors, whereas TP53 mutations were associated with high-stage (P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes were almost mutually exclusive. Our results suggest that FGFR3 and TP53 mutations define separate pathways at initial diagnosis of urothelial cell carcinoma.
This article has been cited by other articles:
|
|
 |
|
  L. Knoops, R. Haas, S. de Kemp, D. Majoor, A. Broeks, E. Eldering, J. P. de Boer, M. Verheij, C. van Ostrom, A. de Vries, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma Blood, August 15, 2007; 110(4): 1116 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Landolfi and K. A. Terio Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53. Vet. Pathol., September 1, 2006; 43(5): 674 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, A. Amoros, A. Tardon, A. Carrato, C. Serra, N. Malats, and F. X. Real Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas J. Clin. Oncol., August 1, 2006; 24(22): 3664 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, et al. TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study. Cancer Res., July 1, 2006; 66(13): 6871 - 6876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-J. Kim, H. C. Kang, S.-G. Jang, K. Kim, S.-A Ahn, H.-J. Yoon, S. N. Yoon, and J.-G. Park Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations Carcinogenesis, March 1, 2006; 27(3): 392 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Crallan, N.T. Georgopoulos, and J. Southgate Experimental models of human bladder carcinogenesis Carcinogenesis, March 1, 2006; 27(3): 374 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Loyant, A. Jaffre, J. Breton, I. Baldi, A. Vital, F. Chapon, S. Dutoit, Y. Lecluse, H. Loiseau, P. Lebailly, et al. Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents Mutagenesis, September 1, 2005; 20(5): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hernandez, E. Lopez-Knowles, J. Lloreta, M. Kogevinas, R. Jaramillo, A. Amoros, A. Tardon, R. Garcia-Closas, C. Serra, A. Carrato, et al. FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis Clin. Cancer Res., August 1, 2005; 11(15): 5444 - 5450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens Carcinogenesis, January 1, 2005; 26(1): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. G. van Rhijn, T. H. van der Kwast, A. N. Vis, W. J. Kirkels, E. R. Boeve, A. C. Jobsis, and E. C. Zwarthoff FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma Cancer Res., March 15, 2004; 64(6): 1911 - 1914. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
